Your browser doesn't support javascript.
loading
P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer.
Le, Hien Thi Thu; Murugesan, Akshaya; Candeias, Nuno R; Ramesh, Thiyagarajan; Yli-Harja, Olli; Kandhavelu, Meenakshisundaram.
Afiliação
  • Le HTT; Molecular Signaling Group, Faculty of Medicine and Health Technology, Tampere University and BioMediTech, P.O.Box 553, 33101, Tampere, Finland.
  • Murugesan A; Molecular Signaling Group, Faculty of Medicine and Health Technology, Tampere University and BioMediTech, P.O.Box 553, 33101, Tampere, Finland.
  • Candeias NR; Department of Biotechnology, Lady Doak College, Thallakulam, Madurai, 625002, India.
  • Ramesh T; Faculty of Engineering and Natural Sciences, Tampere University, Korkeakoulunkatu 8, 33101, Tampere, Finland.
  • Yli-Harja O; LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193, Aveiro, Portugal.
  • Kandhavelu M; Department of Basic Medical Sciences, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Kingdom of Saudi Arabia.
Apoptosis ; 27(3-4): 283-295, 2022 04.
Article em En | MEDLINE | ID: mdl-35129730
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Agonistas do Receptor Purinérgico P2Y / Acetato de Abiraterona Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Agonistas do Receptor Purinérgico P2Y / Acetato de Abiraterona Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article